par Agathe Masson | Mar 31, 2025 | Access to Care, NCD Policy, Actualités
Noncommunicable diseases (NCDs) are among the leading causes of death and disability worldwide, posing an immense burden on healthcare systems, economies, and individuals—especially in countries with a low Human Development Index (HDI). Recognising the urgency of...
par Agathe Masson | Mar 13, 2025 | Access to Care, NCD Partnerships, Actualités
A new article in The Lancet Oncology1 highlights the urgent need for sustainable solutions to improve cancer treatment access in low- and middle-income countries (LMICs). Authored by ATOM Coalition experts, the article outlines key barriers to medicine availability...
par Agathe Masson | Jan 29, 2025 | Access to Care, Healthcare Systems, Actualités
Cervical cancer remains one of the most preventable and treatable cancers. Yet it disproportionately affects women in countries with low Human Development Index (HDI), where screening and treatment services often face systemic challenges. Recognising this, the World...
par Agathe Masson | Déc 13, 2024 | Access to Care, NCD Solutions, Actualités
Every child deserves a fighting chance against cancer, regardless of where they are born. Yet, stark inequalities persist in access to pediatric oncology treatment, especially in low- and middle-income countries (LMICs). As purchasers responsible for securing...
par Agathe Masson | Déc 9, 2024 | Access to Care, NCD Solutions, Actualités
Sickle Cell Disease (SCD) is a genetic blood disorder that affects millions of people worldwide. Between 2010 and 2050, an estimated 14 million babies will be affected globally, with the vast majority born in low- and middle-income countries (LMICs). This staggering...
par Agathe Masson | Déc 9, 2024 | Access to Care, NCD Policy, Actualités
Access to essential treatments is a cornerstone of effective healthcare systems. Both brand-name medicines and generics play vital roles in ensuring that patients receive the care they need. While brand-name medicines are often associated with innovation and...
